Treatment of poor-prognosis sex cord-stromal tumors of the ovary with the combination of bleomycin, etoposide, and cisplatin

Obstetrics and Gynecology
D M GershensonJ T Wharton

Abstract

To investigate the clinical activity of the combination of bleomycin, etoposide, and cisplatin for metastatic ovarian sex cord-stromal tumors of all types and poorly differentiated Sertoli-Leydig cell tumors confined to the ovary. The regimen was administered as follows: bleomycin 10-15 mg/day by continuous intravenous (IV) infusion on days 1-3; etoposide 100 mg/m2 IV per day on days 1-3; cisplatin 100 mg/m2 IV on day 1. End points for analysis included response, progression-free survival, and survival. Nine patients were entered in this trial. The median age was 37 years (range 12-69). Histologic types included adult granulosa cell tumor in five patients, juvenile granulosa cell tumor in one, poorly differentiated Sertoli-Leydig cell tumor in two, and mixed tumor in one. Stage distribution was as follows: stage Ia, two; stage IIc, one; stage IIIc, one; recurrent, five. Of the six patients with measurable disease, two (33%) had a complete response (one surgical and one clinical), and three (50%) had a partial response, for an overall response rate of 83%; one patient had no response. Toxicity was acceptable; two patients had mild bleomycin pulmonary toxicity. Of the three patients with nonmeasurable disease, one relapsed, one d...Continue Reading

References

Feb 1, 1990·Gynecologic Oncology·S ChadhaA Schaberg
Jan 1, 1990·International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists·S A SwansonJ E Wheeler
Nov 15, 1989·Cancer·C L HitchcockE S Wargotz
Feb 1, 1968·Cancer·H J Norris, H B Taylor
Jun 1, 1984·The American Journal of Surgical Pathology·C Zaloudek, H J Norris
Apr 1, 1983·Gynecologic Oncology·G OhelJ G Schenker
Jun 1, 1981·Gynecologic Oncology·E Björkholm, C Silfverswärd
Mar 1, 1995·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·D. TresukosolJ.J. Kavanagh

❮ Previous
Next ❯

Citations

Feb 25, 2011·International Journal of Clinical Oncology·Weizhen LouKeng Shen
Jan 16, 2014·Indian Journal of Surgical Oncology·Vijaykumar Dehannathparambil KottarathilKeechilat Pavithran
Oct 9, 1998·Obstetrics and Gynecology·C A Brewer, D Shevlin
Feb 5, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S PecorelliJ B Vermorken
Feb 28, 2002·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·I A Al-BadawiG C E Stuart
May 2, 2012·Journal of Pediatric Hematology/oncology·Kris Ann P SchultzLindsay Frazier
Aug 8, 2014·Obstetrical & Gynecological Survey·Jessica E StineJohn T Soper
Feb 19, 2000·The Journal of Obstetrics and Gynaecology Research·M AraiH Kuramoto
May 22, 2008·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·P PautierC Lhommé
Sep 18, 2007·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Y-K LeeH-P Lee
May 9, 2007·Clinical Chemistry and Laboratory Medicine : CCLM·Miriam LenhardAlexander Burges
Mar 25, 2014·Journal of Pediatric and Adolescent Gynecology·John L PowellBrian C Shiro
Mar 11, 2004·Journal of Pediatric and Adolescent Gynecology·Eduardo Lara-TorreIan Jaffee
Apr 4, 2013·Taiwanese Journal of Obstetrics & Gynecology·Chia-Sui WengHung-Hsueh Chou
Jul 15, 2015·Taiwanese Journal of Obstetrics & Gynecology·Peng-Hui WangUNKNOWN Taiwanese Gynecologic Oncology Group
May 18, 2010·International Journal of Radiation Oncology, Biology, Physics·Jan HauspyWilfred Levin
Oct 20, 2007·Cancer Treatment Reviews·D PectasidesA Psyrri
Nov 29, 2005·Obstetrics and Gynecology Clinics of North America·Hamid SayarClaire F Verschraegen
Jul 25, 2015·Pediatric Blood & Cancer·Brice FresneauCatherine Patte
Jun 14, 2012·The Journal of Obstetrics and Gynaecology Research·Rani Akhil BhatKwai Lam Yam
Feb 3, 2004·Journal of Cellular and Molecular Medicine·Ancuta Gheorghisan-GalateanuV Horhoianu
Nov 24, 2012·Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology·Huiting XiaoLingying Wu
Feb 10, 2004·Journal of Obstetrics and Gynaecology : the Journal of the Institute of Obstetrics and Gynaecology·M Moodley, J Moodley
May 25, 2015·Gynecologic Oncology·Michelle K WilsonAmit M Oza
Mar 27, 2012·Gynecologic Oncology·Cristina SigismondiGiorgia Mangili
Mar 30, 1999·Gynecologic Oncology·J K WolfD M Gershenson
Apr 30, 2013·Gynecologic Oncology·Giorgia MangiliDomenica Lorusso
Dec 30, 2014·Gynecologic Oncology·Jane L MeiselCarol Aghajanian
Oct 19, 2001·Gynecologic Oncology·J Dubuc-LissoirG Allaire
Dec 14, 2011·Gynecologic Oncology·Marcela G del CarmenJohn O Schorge
Jul 10, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nicoletta ColomboAlessandra Insinga
Sep 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jubilee BrownDavid M Gershenson
Sep 26, 2008·Integrative Cancer Therapies·Georgios V KoukourakisAthanasios Gouliamos

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.